Company: Abbvie Inc.
Job title: Principal Scientist II, Tau Pathobiology
Human in vitro Disease Modeling – Development of Firstin- Class iPSC Models of Endogenous Tau Aggregation 11:15 am
Optimization and QC of a well-known differentiation protocol improve robustness and reproducibility Development of tau seeding models using AD brain-derived or recombinant tau seeds demonstrates that successful templating of endogenous tau requires compatibility between neuronal tau and exogenous seeds In vitro endogenous tau aggregation is neuron subtype-specific, mimicking selective vulnerability observed in ADRead more
day: Day One Track A AM